NCT03070704View on ClinicalTrials.gov

Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

August 16, 2017

Primary Completion Date

March 1, 2019

Study Completion Date

August 16, 2019

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

insulin degludec/liraglutide

Patients will be treated with commercially available Xultophy™ (insulin degludec / liraglutide) according to routine clinical practice at the discretion of the treating physician

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT03070704 - Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India | Biotech Hunter | Biotech Hunter